Journal article
Abelacimab for Prevention of Venous Thromboembolism
Abstract
BACKGROUND: The role of factor XI in the pathogenesis of postoperative venous thromboembolism is uncertain. Abelacimab is a monoclonal antibody that binds to factor XI and locks it in the zymogen (inactive precursor) conformation.
METHODS: In this open-label, parallel-group trial, we randomly assigned 412 patients who were undergoing total knee arthroplasty to receive one of three regimens of abelacimab (30 mg, 75 mg, or 150 mg) administered …
Authors
Verhamme P; Yi BA; Segers A; Salter J; Bloomfield D; Büller HR; Raskob GE; Weitz JI
Journal
The New England Journal of Medicine, Vol. 385, No. 7, pp. 609–617
Publisher
Massachusetts Medical Society
Publication Date
August 12, 2021
DOI
10.1056/nejmoa2105872
ISSN
0028-4793
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAnticoagulantsArthroplasty, Replacement, KneeDose-Response Relationship, DrugEnoxaparinFactor XIFemaleHemorrhageHumansInfusions, IntravenousInjections, SubcutaneousMaleMiddle AgedPartial Thromboplastin TimePostoperative ComplicationsVenous Thromboembolism